How do you approach cisplatin dosing for locally advanced head and neck SCC in HPV-positive and HPV-negative patients?

Weekly cisplatin 40 mg/m² is not yet considered equivalent to high-dose cisplatin 100 mg/m² every three weeks, and high-dose cisplatin remains the preferred regimen for both HPV-positive and HPV-negative locally advanced head and neck squamous cell carcinoma. However, weekly cisplatin is an acceptab...

As Dr. @Dr. First Last points out, the NRG has an active study to address this. 100mg/m2 had been the standard, in part as an old ECOG trial published in abstract only tested a much weaker weekly regimen, i.e., 20 mg/m2, and was negative, while in particular the 2 seminal PORT trials testing cisplat...

We remain one of the few centers in the US that still prescribe high-dose cisplatin, 100 mg/m² every three weeks, to both HPV-positive and HPV-negative patients. Our position has always been that q3-weekly dosing probably has an efficacy advantage over weekly, and the evidence that sits behind it: t...